The global creatinine measurement market is expected to witness significant growth over the forecast period. Creatinine is an endogenous by-product of muscle metabolism. Clinical laboratory measurement of this waste product is used for the assessment of glomerular filtration rate (GFR) that further defines the kidney function of patients. Most of the routine creatinine assays that are in current use include Jaffe’s kinetic methods and enzymatic methods. The global market is segmented on the basis of test type, product, sample, and end use.
The high prevalence of renal disorders is a major factor driving market growth globally. As per estimates of American Kidney Fund, kidney disorders was ninth leading cause of death in the U.S. Approximately 31 million U.S. population suffers from Chronic Kidney Disease (CKD). Moreover, according to the Global Burden of Disease (GBD) estimates, there were around 1.2 million deaths due to cardiovascular disorders in 2015, wherein cardiovascular disorders were stimulated by reduced glomerular filtration rate. This high prevalence has promoted the companies and health organizations to invest in the development of robust renal disorders measurement tools.
The demand of creatinine measurement kits and reagents is also supplemented by an increase in the incidence of other chronic disorders that impact the kidney function. For instance, diabetes and high blood pressure lead to almost 44% and 29% of total kidney failure cases respectively. The market growth is further boosted by an escalation in the global geriatric population which is more prone to renal disorders, supportive government regulations in order to promote renal health, and the advent of monitoring technologies. One of such promising technological advancements includes employment of point of care creatinine measuring devices which serve as a rapid method. This aids in the eradication of the requirement of skilled analytical personnel to accomplish complicated monitoring techniques.
Furthermore, in order to enhance the market growth, National Kidney Disease Education Program’s laboratory working group collaborated with the European Federation of Clinical Chemistry, Laboratory Medicine & International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) to form the Creatinine Standardization Program. This initiative by government agencies resulted in the reduction of interlaboratory variation in creatinine assay calibration which in turn enhanced the accuracy of glomerular filtration rate estimation. Such initiatives assist healthcare professionals in the detection and treatment of several renal diseases, thereby improving patient outcomes.
However, shifting preferences of healthcare professionals towards novel techniques, which include the identification of renal dysfunction biomarkers, and lack of predictive value obtained by creatinine measurement techniques is expected to hamper the market growth.
Major players operating in the creatinine measurement industry include BioAssay Systems, Abcam plc, Arbor Assays, Thermo Fisher Scientific, Randox Laboratories Ltd., Sentinel CH. SpA, DiaSys Diagnostic Systems GmbH, MedTest Holdings, Inc. (Pointe Scientific, Inc.), Abbexa Ltd., and General Atomics, Inc. (Diazyme Laboratories, Inc.). These industrial players are engaged in the development of kits and reagents along with the introduction of novel techniques for successful creatinine detection.
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPR norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."
The most common concern for the governments of all Covid-19 hit nations is the excruciating need to screen for and test large numbers of patients for possible Sars-Cov-2 infection. As a result, most of them are facing major shortages in the supply for diagnostic kits to test for the virus. Diagnostics virology entities are under immense pressure to provide reliable testing kits, and there is a surge in demand for in-vitro or point-of-care testing capacities by labs across a large number of countries. The report will account for Covid19 as a key market contributor.